#Cabozantinib is active after contemporary IO combo in mRCC (ICR analysis, strict 2nd line):
👉 ORR 41% after IO-IO, PFS: 10.9 mo
👉 ORR 28% after TKI-IO, PFS 8.3 mo
👉 supports its use after IO combinations
doi.org/10.1016/j.eu...

📢 Accumulating administrative burdens place clinical trial at risk
🤝 as medical societies and patient advocates we formed the cross-disciplinary Coalition for Reducing Bureaucracy in Clinical Trials.
➡️ Read the Coalition’s 2025 Recommendations here:
bureaucracyincts.eu/coalition-re...